Warren C. Stern, Ph.D.

Senior Vice President – Clinical and Regulatory

 

Dr. Stern is an expert in drug development from pre-IND through NDA. Before Diceros Therapeutics, he was Senior Vice President of Drug Development at AesRx, LLC until it was acquired by Baxter International.  Dr. Stern has led successful pre-IND to Phase 3 drug development programs for several early-stage companies, including QRxPharma, DOV Pharmaceutical, and Jubilant Innovation. Previously he was Senior Vice President of two CROs (PAREXEL International; Cato Research), CEO and President of a drug delivery company and head of product development for several early-stage biotechnology companies. Dr. Stern played a leadership role in the clinical and regulatory development of two blockbuster drugs: Wellbutrin/Zyban and Celexa. Dr. Stern also helped found several biotech companies (RTP Pharma - acquired by SkyePharma; Nobex - acquired by Biocon).

 

Dr. Stern holds over 10 patents and patent applications and has authored over 90 papers on topics in clinical and animal pharmacology research.  He received his Ph.D. from Indiana University and completed a post­ doctoral fellowship at the Boston State Hospital. He received a B.S. from City University of New York.